http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions
-
Halozyme Therapeutics (HALO) Provides Update on Non-Binding Proposal to Combine with Evotec (EVO)
-
Halozyme Provides Update on Non-Binding Proposal to Combine with Evotec
-
Halozyme Therapeutics (HALO) Confirms Proposal to Combine with Evotec (EVO) for €11.00 Per Share in an All-Cash Transaction
-
Halozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash Transaction
-
Evotec SE Reports 9M 2024 Results: Strategic Progress and Successful Expansion Amid Challenging Market Conditions
-
Evotec Announces Sale of API Manufacturing Facility to Monacum Partners
-
Evotec SE to Announce Results for the First Nine Months 2024 on 06 November 2024
-
Evotec and Bristol Myers Squibb Expand Proteomics Partnership
-
Just - Evotec Biologics Opens Cutting-Edge Biologics Facility - J.POD(R) Toulouse, France (EU)
-
Evotec Announces Change in Management Board
-
Evotec SE (EVO) and Pfizer Collaborate to Advance Drug Discovery in France
-
Evotec and Pfizer Collaborate to Advance Drug Discovery in France
-
Just - Evotec Biologics Expands Tech Partnership for Biosimilars with Sandoz
-
Evotec SE: Results of the Annual General Meeting 2024
-
Centogene N.V. (CNTG) and Evotec (EVO) Discover Promising New Molecule to Treat Gaucher Disease
-
CENTOGENE and Evotec Discover Promising New Molecule to Treat Gaucher Disease
-
Evotec (EVO) And Variant Bio Enter Strategic Partnership To Discover And Develop Fibrosis Treatments
-
EVOTEC AND VARIANT BIO ENTER STRATEGIC PARTNERSHIP TO DISCOVER AND DEVELOP FIBROSIS TREATMENTS
-
Evotec-partner Jingxin Receives Approval for EVT201 in China
-
Dewpoint Therapeutics Enters Strategic Partnership with Evotec to Accelerate Oncology Pipeline
-
Galaxy Gaming® and Evolution Extend Licensing Agreement for 10 Years
-
Just - Evotec Biologics Launches Tech Partnership for Biosimilars Development and Commercial Manufacturing
-
RenovoRx Appoints Leesa Gentry as Senior Vice President of Clinical Operations
-
Evotec SE Preliminary Fiscal Year 2022 Results: 'Ahead of the Curve' - Very Strong Performance in a Challenging Year
-
Evotec SE to Announce Preliminary Financial Results for Fiscal Year 2022 on 28 March 2023
-
Evotec SE (EVO) Reports on Progress in Strategic Protein Degradation Partnership with Bristol Myers Squibb
-
Evotec Announces Progress in Strategic Protein Degradation Partnership with Bristol Myers Squibb
-
Evotec and Related Sciences Expand Integrated Drug Discovery and Development Partnership
-
Exscientia Presents Novel Immuno-Oncology Biomarker for EXS-21546 at the ESMO I-O Annual Congress
-
Exscientia plc (EXAI) Receives First CTA Approval to Initiate IGNITE-AI, a Phase 1/2 Trial of EXS-21546 in Patients with Advanced Solid Tumours
-
Exscientia Receives First CTA Approval to Initiate IGNITE-AI, a Phase 1/2 Trial of EXS-21546 in Patients with Advanced Solid Tumours
-
Evotec Completes Acquisition of Central Glass Germany
-
Evotec, CDP Venture Capital and Angelini Ventures Launch Translational Partnership 'Extend' with Leading Italian Academic Institutions
-
Evotec launches PanOmics Data Analysis Platform PanHunter at Bio-IT World
-
TIAP and Evotec Expand LAB150 BRIDGE Partnership to Include Amgen
-
Evotec SE (EVO) Enters Collaboration with Adapsyn
-
Adapsyn Bioscience enters into strategic collaboration with Evotec
-
Just – Evotec Biologics Awarded Contract from the U.S. Department of Defense Under Accelerated Antibodies Program
-
Alpine Immune Sciences (ALPN) and Evotec (EVO) Expand Partnership for Development of ALPN-303
-
Just – Evotec Biologics and Alpine Immune Sciences Expand Partnership for Commercial Process Development of ALPN-303
-
Exscientia plc (EXAI) Reports Topline Data From EXS-21546 Phase 1a Study Demonstrating Targeted A2A Receptor Signaling Inhibition in Healthy Volunteers
-
Exscientia Reports Topline Data From EXS-21546 Phase 1a Study Demonstrating Targeted A2A Receptor Signaling Inhibition in Healthy Volunteers
-
Evotec Enters a Drug Discovery Collaboration with Janssen
-
Evotec SE (EVO) and Almirall Enter Multi-Target Alliance in Medical Dermatology
-
Evotec and Almirall Enter into a Multi-Target Alliance in Medical Dermatology
-
Evotec SE to Announce Results for Fiscal Year 2021 on 12 April 2022
-
Evotec SE (EVO) Announces EUR 7.5M Grant for Development of COVID-19 Therapeutic
-
Evotec Receives € 7.5 m Grant for Development of COVID-19 Therapeutic
-
EQRx and Evotec Announce Integrated Drug Discovery and Development Partnership

